{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:28:31Z","timestamp":1775550511087,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004386","name":"University of Malaya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI098775-03S1"],"award-info":[{"award-number":["R01AI098775-03S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21AI128311"],"award-info":[{"award-number":["R21AI128311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.vaccine.2018.02.065","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:24:10Z","timestamp":1519691050000},"page":"1853-1862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen"],"prefix":"10.1016","volume":"36","author":[{"given":"Mun Peak","family":"Nyon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Te Kent","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Seid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Pollet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin S.","family":"Naceanceno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurodh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Algaissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Hung","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanbo","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Hotez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.02.065_b0005","unstructured":"WHO. Middle East respiratory syndrome coronavirus (MERS-CoV)."},{"key":"10.1016\/j.vaccine.2018.02.065_b0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/5584_2016_133","article-title":"The middle east respiratory syndrome coronavirus \u2013 a continuing risk to global health security","volume":"972","author":"Azhar","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0015","unstructured":"Coalition for Epidemic Preparedness Innovations (CEPI). Vaccine development against prioritized epidemic infectious diseases; 2017."},{"key":"10.1016\/j.vaccine.2018.02.065_b0020","unstructured":"Inovio. Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases. Inovio Pharmaceuticals; 2017."},{"key":"10.1016\/j.vaccine.2018.02.065_b0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/vaccines1030278","article-title":"Innate immune signaling by, and genetic adjuvants for DNA vaccination","volume":"1","author":"Kobiyama","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2018.02.065_b0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0035","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1128\/JVI.02615-14","article-title":"Receptor recognition mechanisms of coronaviruses: a decade of structural studies","volume":"89","author":"Li","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0040","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1517\/14712598.2015.1092518","article-title":"Middle East respiratory syndrome: current status and future prospects for vaccine development","volume":"15","author":"Du","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2018.02.065_b0045","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1586\/14760584.2016.1167603","article-title":"Vaccines for the prevention against the threat of MERS-CoV","volume":"15","author":"Du","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.02.065_b0050","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.065_b0055","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1586\/erv.12.126","article-title":"Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome","volume":"11","author":"Jiang","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.02.065_b0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virusres.2014.11.013","article-title":"Receptor-binding domain-based subunit vaccines against MERS-CoV","volume":"202","author":"Zhang","year":"2015","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.02.065_b0065","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments\u2013the importance of immunofocusing in subunit vaccine design","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.065_b0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0075","doi-asserted-by":"crossref","first-page":"e01651","DOI":"10.1128\/JVI.01651-16","article-title":"Recombinant receptor-binding domains of multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants","volume":"91","author":"Tai","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0080","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/21645515.2017.1296994","article-title":"Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection","volume":"13","author":"Wang","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2018.02.065_b0085","doi-asserted-by":"crossref","first-page":"e81587","DOI":"10.1371\/journal.pone.0081587","article-title":"A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines","volume":"8","author":"Du","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.02.065_b0090","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.sleep.2013.12.020","article-title":"Characteristics of early- and late-onset rapid eye movement sleep behavior disorder in China: a case-control study","volume":"15","author":"Zhou","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.vaccine.2018.02.065_b0095","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1128\/JVI.03427-14","article-title":"Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease","volume":"89","author":"Agrawal","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/JVI.02009-15","article-title":"Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease","volume":"90","author":"Tao","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1008111328771","article-title":"Evaluation of stable and highly productive gene amplified CHO cell line based on the location of amplified genes","volume":"33","author":"Yoshikawa","year":"2000","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2018.02.065_b0110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","article-title":"A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection","volume":"499","author":"Tai","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.02.065_b0115","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.1038\/ncomms9223","article-title":"Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody","volume":"6","author":"Ying","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.02.065_b0120","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies","volume":"88","author":"Ying","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0125","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1128\/JVI.00433-14","article-title":"A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein","volume":"88","author":"Du","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0130","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.02.065_b0135","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/bit.24776","article-title":"Optimized signal peptides for the development of high expressing CHO cell lines","volume":"110","author":"Kober","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2018.02.065_b0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14728222.2017.1271415","article-title":"MERS-CoV spike protein: a key target for antivirals","volume":"21","author":"Du","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.vaccine.2018.02.065_b0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4236\/abb.2013.412135","article-title":"Evaluation of transfection methods for transient gene expression in Chinese hamster ovary cells","volume":"4","author":"Sou","year":"2013","journal-title":"Adv Biosci Biotechnol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0150","first-page":"257","article-title":"Gene expression in Mammalian cells and its applications","volume":"3","author":"Khan","year":"2013","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.vaccine.2018.02.065_b0155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/337525a0","article-title":"Designing CD4 immunoadhesins for AIDS therapy","volume":"337","author":"Capon","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.02.065_b0160","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.vaccine.2011.01.113","article-title":"Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice","volume":"29","author":"Konduru","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.065_b0165","doi-asserted-by":"crossref","first-page":"10542","DOI":"10.1128\/JVI.05441-11","article-title":"A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection","volume":"85","author":"Lu","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0170","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1128\/JVI.01241-10","article-title":"Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines","volume":"85","author":"Loureiro","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0175","doi-asserted-by":"crossref","first-page":"10467","DOI":"10.1007\/s00253-015-6952-z","article-title":"APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice","volume":"99","author":"Soleimanpour","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0180","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: new developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2018.02.065_b0185","doi-asserted-by":"crossref","first-page":"e30083","DOI":"10.1371\/journal.pone.0030083","article-title":"Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds","volume":"7","author":"Wozniak-Knopp","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.02.065_b0190","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10616-013-9633-8","article-title":"A plea to reduce or replace fetal bovine serum in cell culture media","volume":"65","author":"Gstraunthaler","year":"2013","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2018.02.065_b0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/ph6050579","article-title":"Advances in Mammalian cell line development technologies for recombinant protein production","volume":"6","author":"Lai","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.vaccine.2018.02.065_b0200","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1128\/JVI.01048-13","article-title":"Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development","volume":"87","author":"Du","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.065_b0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0022-1759(92)90092-8","article-title":"Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction","volume":"152","author":"Coloma","year":"1992","journal-title":"J Immunol Methods"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T20:26:40Z","timestamp":1535056000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18302524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":41,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0264410X18302524"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}